Funded by LUNGevity Foundation, A Breath of Hope Foundation, and Partnership for Cures
Sreenath Sharma, PhD
Massachusetts General Hospital
Boston
Jeffery Settleman, MD, PhD
Massachusetts General Hospital
Boston
MA
Patients with EGFR mutations are treated with EGFR drugs such as gefitinib (Iressa) and erlotinib (Tarceva). However, the cancer cells eventually develop resistance to these drugs. Dr. Sharma is aiming to understand the processes by which non-small cell lung cancer cells develop resistance to gefitinib and erlotinib as well as how these processes can be targeted to develop new therapeutic strategies for patients in whom gefitinib and erlotinib have failed.